Dynamic Technology Lab Private Ltd Buys Shares of 17,366 Puma Biotechnology, Inc. (NASDAQ:PBYI)

Dynamic Technology Lab Private Ltd bought a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,366 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

A number of other institutional investors also recently bought and sold shares of PBYI. American Century Companies Inc. lifted its holdings in Puma Biotechnology by 98.5% in the second quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock valued at $2,409,000 after acquiring an additional 366,653 shares during the period. Affinity Asset Advisors LLC purchased a new stake in Puma Biotechnology in the second quarter worth about $815,000. Frazier Life Sciences Management L.P. increased its position in Puma Biotechnology by 8.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after buying an additional 246,264 shares in the last quarter. Los Angeles Capital Management LLC purchased a new stake in Puma Biotechnology in the third quarter worth about $627,000. Finally, Great Point Partners LLC increased its position in Puma Biotechnology by 10.6% in the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after buying an additional 142,916 shares in the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Stock Performance

NASDAQ:PBYI opened at $3.27 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 12-month low of $2.22 and a 12-month high of $7.73. The stock has a 50-day moving average price of $2.86 and a 200 day moving average price of $3.09. The stock has a market capitalization of $160.52 million, a P/E ratio of 6.81 and a beta of 1.08.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.10. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. The firm had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. During the same quarter last year, the business posted $0.12 earnings per share. Equities research analysts forecast that Puma Biotechnology, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the company. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Puma Biotechnology in a research report on Wednesday, November 20th.

Puma Biotechnology Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.